Jens Hillengass is an Oncology physician affiliated with Roswell Park Comprehensive Cancer Center. OpenAlex indexes 41 publications with 245 citations (h-index 9); ClinicalTrials.gov lists 8 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Elm And Carlton Streets
Buffalo, NY 142630001
Telephone
716-845-2300Registry record last updated 12 Aug 2019.
Clinical trials
- Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease
Sponsor: Roswell Park Cancer Institute
- SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Sponsor: Roswell Park Cancer Institute
- Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma
Sponsor: Roswell Park Cancer Institute
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
15 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year20252 payments
- Siemens Medical Solutions USA, Inc.Program year20251 payment
- Janssen Research & Development, LLCProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
2 NIH research awards on record, funded 2025–2026 per NIH RePORTER. The latest:
- Movement is medicine in multiple myeloma: elucidating exercise-mediated immune and metabolic biomarkers that predict treatment response in the bone marrow tumor microenvironment
Roswell Park Cancer Institute Corp
FY2026$718,490R01CA304003 - Investigation of the effects of CXCR1/2 inhibition on the immune microenvironment of patients with multiple myeloma
Roswell Park Cancer Institute Corp
FY2025$173,500R03CA299053
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Igor Puzanov, MD
Roswell Park Comprehensive Cancer Center
Philip McCarthy, MD
Roswell Park Comprehensive Cancer Center
Saby George, MD
Roswell Park Comprehensive Cancer Center
Eunice Wang, MD
Roswell Park Comprehensive Cancer Center
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”